Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.71 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 3/20 | 0.43 |
| ▸ | CES1 | P23141 | 3/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7737049 | 0.92 | HRH3 (0.81) | HRH3HSP90AA1FAAHALDH1A1MEN1 | |
| SCHEMBL3760754 | 0.92 | HRH3 (0.81) | HRH3HSP90AA1FAAHALDH1A1MEN1 | |
| SCHEMBL1221877 | 0.92 | HRH3 (0.81) | HRH3HSP90AA1FAAHALDH1A1MEN1 | |
| SCHEMBL16214678 | 0.92 | HRH3 (0.81) | HRH3HSP90AA1FAAHALDH1A1MEN1 | |
| SCHEMBL2907984 | 0.92 | HRH3 (0.81) | HRH3HSP90AA1FAAHALDH1A1MEN1 | |
| SCHEMBL10628119 | 0.91 | HRH3 (0.88) | HRH3FAAHALDH1A1MEN1KMT2A | |
| SCHEMBL10628125 | 0.91 | HRH3 (0.88) | HRH3FAAHALDH1A1MEN1KMT2A | |
| SCHEMBL10445885 | 0.90 | HRH3 (0.77) | HRH3HSP90AA1FAAHALDH1A1MEN1 | |
| SCHEMBL14036928 | 0.89 | HRH3 (0.60) | HRH3HSP90AA1FAAHALDH1A1MEN1 | |
| SCHEMBL8498722 | 0.87 | HRH3 (0.69) | HRH3HSP90AA1FAAHALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-60123451-A | — | — | None | — | — | JP | disclosed |
| US-12024533-B2 | Antimicrobial organosilanes | TOPIKOS SCIENTIFIC, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230143708-A1 | ANTIMICROBIAL ORGANOSILANES | TOPIKOS PHARMACEUTICALS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-0968998-A1 | Cosmetic compositions, ceramide analogues with anti-elastase activity and process for their preparation | ELF ATOCHEM S.A. (FR) | 2000-01-05 | — | — | EP | disclosed |
| US-4762829-A | ANTICOAGULANTS | EISAI CO., LTD. (JP) | 1988-08-09 | — | — | US | disclosed |
| US-4742058-A | AMIDES, ANTICOAGULANTS | EISAI CO., LTD. (JP) | 1988-05-03 | — | — | US | disclosed |
| JP-S60123451-A | POLYPRENYL BASED COMPOUND AND PRODUCTION THEREOF AND PHARMACEUTICAL CONTAINING THE SAME | EISAI CO LTD | 1985-07-02 | — | — | JP | disclosed |
| EP-0110397-A2 | Polyprenyl compound and drug containing the same | Eisai Co., Ltd. (JP) | 1984-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024533-B2 | Antimicrobial organosilanes | ARG1, ACMSD, AAAS | HRH3 790/4885HSP90AA1 1012/4885FAAH 3503/4885 |
| US-20230143708-A1 | ANTIMICROBIAL ORGANOSILANES | ARG1, ACMSD, AAAS | HRH3 790/4885HSP90AA1 1012/4885FAAH 3503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.